Control-IQ+ Technology
Now available for ages 2+
Tandem Diabetes Care insulin pumps are now powered by Control-IQ+ technology — the only predictive algorithm with AutoBolus, so you can start seeing improvements on Day 1.1
Automation for Tighter Control
Helps Prevent Highs
Control-IQ+ technology increases basal insulin dosing and uses AutoBolus (up to one an hour) if sensor glucose is predicted to be high.*
Helps Prevent Lows
Control-IQ+ technology can decrease or stop basal insulin if sensor glucose is predicted to be low. This can help improve time in range overnight and during the day.
Now Available for Ages 2+
Expanded age and weight indications for very small and very large insulin requirements.
Temp Basal Rate
Temp Basal Rate option to personalize insulin delivery for changing needs during automation.
Extended Bolus
The only system with an extended bolus, up to eight hours, during automated insulin delivery.
Control-IQ+ Technology
The only system with AutoBolus
Only Control-IQ+ has a true automatic correction bolus.* If glucose is predicted to be above 180 mg/dL, an AutoBolus will be delivered.
Control-IQ+ with AutoBolus has demonstrated better A1c results, even for people who occasionally miss meal boluses.2
Best-in-Class Outcomes
Proven results with Tandem Diabetes Care automated insulin delivery systems.
Average Time in Range Increase on Day 11
Time in Range3†
Overnight Time in Range1
Reduction in A1c (Even if you rarely bolus!)2
Control-IQ+ technology includes optional activity settings that adjust the range of treatment values.
Sleep Activity
Uses a narrower and lower range of treatment values to help guard against lows and highs while sleeping.
Exercise Activity
Uses a narrower and higher range of treatment values to help guard against lows during activity.
Whether you want the tiny and powerful Tandem Mobi, or the all-in-one t:slim X2 pump, you can choose the automated insulin delivery system to fit your lifestyle.
A Tandem Diabetes Care Specialist will help you get started.
Try Our PumpsFree Virtual Demos
Test drive the easy-to-use interfaces of either Tandem Mobi or t:slim X2 automated insulin delivery systems, with no obligation.
Testimonials
See what people are saying about the Tandem automated insulin delivery and how it is changing their lives.
Infusion Sets
Choose from a variety of cannula materials, tubing lengths, and insertion angles to fit all your needs.
Innovative Tools
Our mobile and cloud-based applications are designed to help you better manage your diabetes.
What's next?
Whether you're ready to get a Tandem insulin pump, or looking to check insurance coverage, you’ll find everything you need here.
* A bolus is a single, large dose of medicine. If glucose values are predicted to be above 180 mg/dL Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value.
† With optimized correction factor based on “rule of less than 1600.”
References
Note: Studies were conducted using a t:slim X2 insulin pump with Control-IQ technology and a Dexcom G6 sensor.
1. Beck RW, et al. Diabetes Technol Ther. 2023;25(5):329-342.
2. Akturk HK, et al. Diabetes Sci Technol. 2022;24(10):779-783.
3. Messer LH, Breton M. Diabetes Technol Ther. 2023;25(12):877-882.
Important Safety Information
RX ONLY.
Indications for Use
Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater.
Warning: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely.
Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.